Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.

Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2013 Apr;75(4):1068-80. doi: 10.1111/j.1365-2125.2012.04406.x.

2.

Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.

Mehrotra N, Tang L, Phelps SJ, Meibohm B.

Pharmacotherapy. 2012 May;32(5):408-19. doi: 10.1002/j.1875-9114.2012.01029.x. Epub 2012 Apr 9.

PMID:
22488303
3.

Vancomycin prescription in neonates and young infants: toward a simplified dosage.

Oudin C, Vialet R, Boulamery A, Martin C, Simon N.

Arch Dis Child Fetal Neonatal Ed. 2011 Sep;96(5):F365-70. doi: 10.1136/adc.2010.196402. Epub 2011 Mar 6.

PMID:
21378399
4.

Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Lo YL, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG.

Antimicrob Agents Chemother. 2010 Jun;54(6):2626-32. doi: 10.1128/AAC.01370-09. Epub 2010 Apr 12.

5.

Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.

Marqués-Miñana MR, Saadeddin A, Peris JE.

Br J Clin Pharmacol. 2010 Nov;70(5):713-20. doi: 10.1111/j.1365-2125.2010.03736.x.

6.

Vancomycin population pharmacokinetics in neonates.

de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN.

Clin Pharmacol Ther. 2000 Apr;67(4):360-7.

PMID:
10801244
7.

Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis.

Deng C, Liu T, Zhou T, Lu H, Cheng D, Zhong X, Lu W.

Int J Clin Pharmacol Ther. 2013 May;51(5):407-15. doi: 10.5414/CP201842.

PMID:
23458230
8.

Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates.

Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CM, Frymoyer A.

Infect Dis Ther. 2015 Jun;4(2):187-98. doi: 10.1007/s40121-015-0067-9. Epub 2015 May 22.

9.

Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K.

Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67.

10.

Serum levels of vancomycin: is there a prediction using doses in mg/kg/day or m(2)/day for neonates?

Romanelli RM, Anchieta LM, Fernandes JC, Lima MA, Souza TM, Rosado V, Clemente WT, Camargos PA.

Braz J Infect Dis. 2016 Sep-Oct;20(5):451-6. doi: 10.1016/j.bjid.2016.06.008. Epub 2016 Aug 12.

11.

Vancomycin: pharmacokinetics and administration regimens in neonates.

de Hoog M, Mouton JW, van den Anker JN.

Clin Pharmacokinet. 2004;43(7):417-40. Review.

PMID:
15139793
12.

Implications of serum creatinine measurements on GFR estimation and vancomycin dosing in children.

Neuman G, Nulman I, Adeli K, Koren G, Colantonio DA, Helldén A.

J Clin Pharmacol. 2014 Jul;54(7):785-91. doi: 10.1002/jcph.281. Epub 2014 Mar 11.

PMID:
24596064
13.

Assessment of optimal initial dosing regimen with vancomycin pharmacokinetics model in very low birth weight neonates.

Kato H, Hagihara M, Nishiyama N, Koizumi Y, Mikamo H, Matsuura K, Yamagishi Y.

J Infect Chemother. 2017 Mar;23(3):154-160. doi: 10.1016/j.jiac.2016.11.009. Epub 2016 Dec 22.

PMID:
28017667
14.

Evaluation of the vancomycin dosage regimen based on serum creatinine used in the neonatal intensive care unit.

Irikura M, Fujiyama A, Saita F, Fukushima S, Kitaoka H, Fukuda T, Kawase A, Kondo Y, Ishitsuka Y, Kondo G, Maeda T, Yukawa E, Irie T.

Pediatr Int. 2011 Dec;53(6):1038-44. doi: 10.1111/j.1442-200X.2011.03441.x.

PMID:
21810150
15.

Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.

Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2014 Jun;58(6):3191-9. doi: 10.1128/AAC.02564-13. Epub 2014 Mar 24.

16.

Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.

Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, Pidoux O, Badr M, Picaud JC.

Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F418-21. doi: 10.1136/adc.2007.128280. Epub 2008 May 1. Erratum in: Arch Dis Child Fetal Neonatal Ed. 2009 Jan;94(1):F78.

PMID:
18450803
17.

Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.

Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E.

Arch Dis Child. 2013 Jun;98(6):449-53. doi: 10.1136/archdischild-2012-302765. Epub 2012 Dec 19.

PMID:
23254142
18.

Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study.

Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T.

Pediatrics. 1999 Apr;103(4):e48.

PMID:
10103340
19.

Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.

Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC.

Ann Pharmacother. 2011 Jun;45(6):757-63. doi: 10.1345/aph.1P634. Epub 2011 Jun 7.

PMID:
21652786
20.

Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M.

Br J Clin Pharmacol. 2010 Aug;70(2):201-12. doi: 10.1111/j.1365-2125.2010.03679.x.

Supplemental Content

Support Center